Reversion of multidrug resistance in tumor by biocompatible nanomaterials

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 8, 2010, Pages 737-745

  Zhang, H ^a   Jiang, H ^a   Wang, X ^a   Chen, Baoan ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Biocompatible nanomaterials; Cancers; Multidrug resistance; Nanotechnology; Reversal MDR agents; Tumor therapeutics

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; LANIQUIDAR; MONOCLONAL ANTIBODY; NANOMATERIAL; PACLITAXEL; QUINIDINE; TARIQUIDAR; TRANSCRIPTION FACTOR; VALSPODAR; VERAPAMIL; VINBLASTINE; ZOSUQUIDAR; ANTINEOPLASTIC AGENT; BIOMATERIAL; DRUG CARRIER;

APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CANCER CHEMOTHERAPY; CANCER THERAPY; CELLULAR IMMUNITY; CHINESE MEDICINE; DRUG DELIVERY SYSTEM; DRUG MECHANISM; GENE TECHNOLOGY; HUMAN; IN VIVO STUDY; LYMPHOCYTE; MULTIDRUG RESISTANCE; NONHUMAN; SURFACE PROPERTY; THERAPY EFFECT; CHEMISTRY; DRUG RESISTANCE; IMMUNOLOGY; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOSTRUCTURES; NEOPLASMS;

EID: 77954755280     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955710791572460     Document Type: Article

References (78)

1. Ravna, A.W.; Sager, G. Molecular modeling studies of ABC transporters involved in multidrug resistance. Mini-Rev. Med. Chem., 2009, 9, 186-193.
2. Coley, Helen M. Mechanisms and consequences of chemotherapy resistance in breast cancer. EJC Suppl., 2009, 7, 3-7.
3. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol., 2005, 2, 275-292.
4. Bosch, I.; Croop, J. P-glycoprotein multidrug resistance and cancer. Biochim. Biophys. Acta-Rev. Cancer, 1996, 1288, F37-54.
5. Komarova, N.L.; Wodarz, D. Drug resistance in cancer: Principles of emergence and prevention. Proc. Natl. Acad. Sci. U. S. A., 2005, 102, 9714-9719.
6. Kruh, G.D. Introduction to resistance to anticancer agents. Oncogene, 2003, 22, 7262-7264.
7. Higgins, C.F; Gottesman, M. M. Is the multidrug transporter a flippase. Trends Biochem.Sci., 1992, 17, 18-21.
8. Gottesman, M.M.; Pastan, I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 1993, 62, 385-427.
9. Khdair, A.; Gerard, B.; Handa, H.; Mao, G.Z.; Shekhar, M.P.V.; Panyam, P. Surfactant-polymer nanoparticles enhance the effectiveness of anticancer photodynamic therapy. Mol. Pharm., 2008, 5, 795-807.
10. Mitra, S.; Gaur, U.; Gosh, P.C.; Maitra, A.N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Release, 2001, 74, 317-323.
11. Han, M.; He, C.X.; Fang, Q.L.; Yang, X.C.; Diao, Y.Y.; Xu, D.H.; He, Q.J.; Hu, Y.Z.; Liang, W.Q.; Yang, B.; Gao, J.Q. A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo. Pharm. Res., 2009, 26, 926-935.
12. Wang, X.M.; Zhang, R.Y.; Wu, C.H.; Dai, YY.; Song, M.; Gutmann, S.; Gao, F.; Lv, G.; Li, J.Y.; Li, X.M.; Guan, Z.Q.; Fu, D.G.; Chen, B.A. The application of Fe3O4 nanoparticles in cancer research: A new strategy to inhibit drug resistance. J. Biomed. Mater. Res. Part A, 2007, 80A, 852-860.
13. Zhang, R.Y.; Wang, X.M.; Wu, C.H.; Song, M.; Li, J.Y.; Lv, G.; Zhou, J.; Chen, C.; Dai, Y.Y.; Gao, F.; Fu, D.G.; Li, X.M.; Guan, Z.Q.; Chen, B.A. Synergistic enhancement effect of magnetic nanoparticles on anticancer drug accumulation in cancer cells. Nanotechnology, 2006, 17, 3622-3626.
14. Murakami, T; Tsuchida, K. Recent advances in inorganic nanoparticle-based drug delivery systems. Mini-Rev. Med. Chem., 2008, 8, 175-183.
15. Maeda, H.; Bharate, G.Y.; Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 2009, 71,409-419.
16. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat. Rev. Cancer, 2002, 2, 48-58.
17. Zeng, H.; Bain, L. J.; Belinsky, M. G. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res., 1999, 59, 5964-5967.
18. Kruh, G.D.; Zeng, H.; Rea, P.A. MRP subfamily transporters and resistance to anticancer agents. J. Bioenerg. Biomembr., 2001, 33, 493-501.
19. Belinsky, M.G.; Chen, Z.S; Shchaveleva, I. Zeng, H.; Kruh, G.D. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res., 2002, 62, 6172-6177.
20. Albermann, N.; Schmitz-Winnenthal, F.H.; Zgraggen, K.; Volk, C.; Hoffmann, M.M.; Haefeli, W.E.; Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol., 2005, 70, 949-958.
21. Doyle, L.A.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22, 7340-7358.
22. List, A.F.; Spier, C.S.; Grogan, T.M.; Johnson, C.; Roe, D.J.; Greer, J.P.; Wolff, S.N.; Broxterman, H.J.; Scheffer, G.L.; Scheper, R.J.; Dalton, W.S. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 1996, 87, 2464-2469.
23. Burg, D.; Riepsaame, J.; Pont, C.; Mulder, G.; van de Water, B. Peptide-bond modified glutathione conjugate analogs modulate GST pi function in GSH-conjugation, drug sensitivity and JNK signaling. Biochem. Pharmacol., 2006, 71, 268-277.
24. Kimura, S.; Imagawa, Y.; Satake, K.; Tsukuda, M. The relationship of the human glutathione S-transferase P1 polymorphism and chemotherapeutic sensitivity in head and neck squamous carcinoma. Int. J. Mol. Med., 2004, 14, 185-189.
25. Gilroy, K.L.; Leontiou, C.; Padget, K.; Lakey J.H.; Austin, C.A. mAMSA resistant human topoisomerase II beta mutation G465D has reduced ATP hydrolysis activity. Nucleic Acids Res., 2006, 34, 1597-1607.
26. Fabbro, D.; Ruetz, S.; Bodis, S.; Pruschy, M.; Csermak, K.; Man, A.; Campochiaro, P.; Wood, J.; Oreilly, T.; Meyer, T. PKC412 - a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des., 2000, 15, 17-28.
27. Palissot, V.; Morjani, H.; Belloc, F. From molecular characteristics to cellular events in apoptosis-resistant HL-60 cells. Int. J. Oncol., 2005, 26, 825-834.
28. Bentires-Alj, M.; Barbu, V.; Fillet, M.; Chariot, A.; Relic, B.; Jacobs, N.; Gielen, J.; Merville, M.P.; Bours, V. NF-kappa B transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene, 2003, 22, 90-97.
29. Han, H.K.; Han, C.Y.; Cheon, E.P.; Lee, J.; Kang, K.W. Role of hypoxia-inducible factor-alpha in hepatitis-B-virus X proteinmediated MDR1 activation. Biochem. Biophys. Res. Commun., 2007, 357, 567-573.
30. Blanca, S.P.; Enrique, P.C.; Lucia, T.C. Alma, C.B.; Alma, R.V.; Luis, B.B.; Alfonso, D.G. Global DNA hypermethylation associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine. J. Transl. Med., 2006, 4, 32-44.
31. Toyota, M.; Kopecky, K.J.; Toyota, M.O.; Jair, K.W.; Willman, C.L.; Issa, J.P.J. Methylation profiling in acute myeloid leukemia. Blood, 2001, 97, 2823-2829.
32. Sung, S.Y.; Johnstone, P.A.S. Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. Curr. Probl. Cancer, 2007, 31, 36-100.
33. Hazlehurst, L.A.; Landowski, T.H.; Dalton, W.S. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene, 2003, 22, 7396-7402.
34. Krishna, R.; Mayer, L.D. Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 2000, 11, 265-283.
35. Hanibuchi, M.; Yano, S.; Nishioka, Y.; Yanagawa, H.; Miki, T.; Sone, S. Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966. Clin. Exp. Metastasis, 2001, 18, 353-360.
36. Takahashi, M.; Misawa, Y.; Watanabe, N.; Kawanishi, T.; Tanaka, H.; Shigenobu, K.; Kobayashi, Y. Role of P-glycoprotein in human natural killer-like cell line-mediated cytotoxicity. Exp. Cell Res., 1999, 253, 396-402.
37. Azuma, E.; Masuda, S.; Qi, J.; Kumamoto, T.; Hirayama, M.; Nagai, M.; Hiratake, S.; Umemoto, M.; Komada, Y.; Sakurai, M. Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias. Eur. J. Haematol., 1997, 59, 14-19.
38. Park, S.J.; Wu, C.H.; Choi, M.R.; Najafi, F.; Emami, A.; Safa, A.R. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem. Pharmacol., 2006, 72, 293-307.
39. Lage, He. Therapeutic potential of RNA interference in drug resistant cancers. Future Oncol., 2009, 5, 169-185.
40. Xu, W.L.; Shen, H.L.; Chen, B.A.; Xia, W.; Gao, F.; Zhang, Y.N. Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk. Res., 2006, 30, 407-413.
41. Nomura, T.; Koreeda, N.; Yamashita, F.Y.; Hashida, M. Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharm. Res., 1998, 15, 128-132.
42. Blanco, E.; Kessinger, C.W.; Sumer, B.D.; Gao, J. Multifunctional micellar nanomedicine for cancer therapy. Exp. Biol. Med., 2009, 234, 123-131.
43. Matsumura, Y.; Kataoka, K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci., 2009, 100, 572-579.
44. Peetla, C.; Labhasetwar, V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir, 2009, 25, 2369-2377.
45. Thevenot, P.; Cho, J.; Wavhal, D.; Timmons, R.B.; Tang, L.P. Surface chemistry influences cancer killing effect of TiO2 nanoparticles. Nanomedicine:N.B.M., 2008, 4, 226-236.
46. Reddy, L.H. Drug delivery to tumours: recent strategies. J. Pharm. Pharmacol., 2005, 57, 1231-1242.
47. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Li, Y.Q.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev., 2007, 59, 491-504.
48. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54, 631-651.
49. Gref, R.; Minamitake, Y; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263, 1600-1603.
50. Alexiou, C.; Arnold, W.; Klein, R.J.; Parak, F.G.; Hulin, P. Bergemann, C.; Erhardt, W.; Wagenpfeil, S.; Lubbe, A. S. Locoregional cancer treatment with magnetic drug targeting. Cancer Res., 2000, 60, 6641-6648.
51. Oyewumi, M. O.; Liu, S. Q.; Moscow, J. A.; Mumper, R. J. Specific association of thiamine-coated gadolinium nanoparticles with human breast cancer cells expressing thiamine transporters. Bioconjug. Chem., 2003, 14, 404-411.
52. El Bayoumil, T.; Torchilin, V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, longcirculating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res., 2009, 15, 1973-1980.
53. Kirpotin, D.B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K.N.; Ulrik, B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66, 6732-6740.
54. Verdun, C.; Brasseur, F.; Vranckx, H.; Couvreur, P.; Roland, M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol., 1990, 26, 13-18.
55. Vauthier, C.; Dubernet, C.; Chauvierre, C.; Brigger, I.; Couvreur, P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control. Release, 2003, 93, 151-160.
56. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol. Rev., 2001, 53, 283-318.
57. Zhang, C.G.; Miao, J.; Dai, Y.Q.; Du, Y.Z.; Yuan, H.; Hu, F.Q. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int. J. Pharm., 2008, 361, 239-244.
58. Soma, C.E.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin in polyalkylcyanoacrylate nanoparticles. Biomaterials, 2000, 21, 1-7.
59. Yadav, E.; van Vlerken, L.E.; Little, S.R.; Amiji, M.M. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother. Pharmacol., 2009, 63, 711-722.
60. Ohulchanskyy, T.Y.; Roy, I.; Goswami, L.N.; Chen, Y.; Bergey, E.J.; Pandey, R.K.; Oseroff, A.R.; Prasad, P.N. Organically modified silica nanoparticles with covalently incorporated photosensitizer for photodynamic therapy of cancer. Nano Lett., 2007, 7, 2835-2842.
61. Kohler, N.; Sun, C.; Wang, J.; Zhang, M.Q. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir, 2005, 21, 8858-8864.
62. Tao, X.; Chen, H.; Sun, X.J.; Chen, H.F.; Roa, W.H. Formulation and cytotoxicity of doxorubicin loaded in self-assembled biopolyelectrolyte microshells. Int. J. Pharm., 2007, 336, 376-381.
63. Kim, J.Y.; Choi, S.J.; Oh, J.M.; Park, T.; Choy, J.H. Anticancer drug-inorganic nanohybrid and its cellular interaction. J. Nanosci. Nanotechnol., 2007, 7, 3700-3705.
64. Li, J.Y.; Wang, X.M.; Wang, C.X.; Chen, B.A.; Dai, Y.Y.; Zhang, R.Y.; Song, M.; Lv, G.; Fu, D.G. The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells. ChemMedChem, 2007, 2, 374-378.
65. Li, J.Y.; Wu, C.H.; Gao, F.; Zhang, R.Y.; Lv, G.; Fu, D.G.; Chen, B.A.; Wang, X.M. In vitro study of drug accumulation in cancer cells via specific association with CdS nanoparticles. Bioorg. Med. Chem. Lett., 2006, 16, 4808-4812.
66. Chen, B.A.; Dai, Y.Y.; Wang, X.M.; Zhang, R.Y.; Xu, W.L.; Shen, H.L.; Gao, F.; Sun, Q.; Deng, X.J.; Ding, J.H.; Gao, C.; Sun, Y.Y.; Cheng, J.; Wang, J.; Zhao, G.; Chen, N.N. Synergistic effect of the combination of nanoparticulate Fe3O4 and Au with daunomycin on K562/A02 cells. Int. J. Nanomed., 2008, 3, 343-350.
67. Song, M.; Zhang, R.Y.; Dai, Y.Y.; Gao, F.; Chi, H.M.; Lv, G.; Chen, B.A.; Wang, X.M. The in vitro inhibition of multidrug resistance by combined nanoparticulate titanium dioxide and UV irradition. Biomaterials, 2006, 27, 4230-4238.
68. Jabr-Milane, L.S.; van Vlerken, L.E. Yadav, S.; Amiji, M.M. Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev., 2008, 34, 592-602.
69. Rapoport, N.Y. Combined cancer therapy by micellar-encapsulated drug and ultrasound. Int. J. Pharm., 2004, 277, 155-162.
70. Marin, A.; Sun, H.; Husseini, G.A.; Pitt, W.G.; Christensen, D.A.; Rapoport, N.Y. Drug delivery in pluronic micelles: effect of high frequency ultrasound on drug release from micelles and intracellular uptake. J. Control. Release, 2002, 84, 39-47.
71. Venne, A.; Li, S.; Mandeville, R.; Kabanov, A.; Alakhov, V. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drugresistant cells. Cancer Res., 1996, 56, 3626-3629.
72. Batrakova, E.V.; Dorodnych, T.Y.; Klinskii, E.Y.; Kliushnenkova, E.N.; Shemchukova, O.B.; Goncharova, O.N.; Arjakov, S.A.; Alakhov, V.Y.; Kabanov, A.V. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer, 1996, 74, 1545-1552.
73. Alakhov, V.; Klinski, E.; Li, S.; Pietrzynski, G.; Venne, A.; Batrakova, E.V.; Bronitch, T.; Kabanov, A. Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloid Surf. B-Biointerfaces, 1999, 16, 113-134.
74. Sharma, A.K.; Zhang, L; Li, S.; Keely, D.L.; Alakhov, V.Y.; Batrakova, Elena; Kabanov, A.V. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J. Control. Release, 2008, 131, 220-227.
75. Zhang, X.X.; Gan, Y.; Gan, L.; Nie, S.F.; Pan, W.S. PEGylated nanostructured lipid carriers loaded with 10-hydroxycamptothecin: an efficient carrier with enhanced anti-tumour effects against lung cancer. J. Pharm. Pharmacol., 2008, 60, 1077-1087.
76. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M.; Watanabe, N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br. J. Cancer, 2004, 91, 1775-1781.
77. Mizumura, Y.; Matsumura, Y.; Yokoyama, M.; Okano, T.; Kawaguchi, T.; Moriyasu, F.; Kakizoe, T. Incorporation of the anticancer agent KRN5500 into polymeric micelles diminishes the pulmonary toxicity. Jpn. J. Cancer Res., 2002, 93, 1237-1243.
78. Matsumura, Y. Poly (amino acid) micelle nanocarriers in preclinical and clinical studies. Adv. Drug Deliv. Rev., 2008, 60, 899-914.